Business Context and Reporting Period
This summary is based on the Form 10-Q filed by Enochian Biosciences, Inc., not Lunai Bioworks Inc. The filing covers the quarter and six months ended December 31, 2019, within the company’s fiscal year ending June 30. Enochian is a preclinical biotechnology company developing genetically modified cellular and immune-therapy technologies for HIV, cancer, and related indications. The filing is unaudited.
Key Financial Metrics
| Metric | Three Months Ended Dec. 31, 2019 | Six Months Ended Dec. 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.818 million | $5.261 million |
| Loss from operations | $2.818 million | $5.261 million |
| Net loss | $1.721 million | $5.804 million |
| Basic and diluted loss per share | $0.04 | $0.13 |
| Operating cash flow | Not separately provided | $(4.376) million |
- General and administrative expense was $2.235 million for the quarter and $4.136 million for the six-month period.
- Research and development expense was $561,468 for the quarter and $1.082 million for the six-month period.
- Cash was $8.627 million at December 31, 2019, compared with $12.282 million at June 30, 2019. Working capital was $7.973 million, compared with $11.385 million at June 30, 2019.
- Total assets were $178.360 million, including $154.824 million of indefinite-lived license assets and $11.640 million of goodwill.
- Total liabilities were $7.077 million, including $4.317 million of contingent consideration and $1.931 million of operating lease liabilities. The filing does not identify material conventional debt or external borrowings.
- Net cash used in investing activities was $132,321, principally for property and equipment. Net cash provided by financing activities was $1.000 million from warrant exercises.
- Cash decreased by $3.656 million during the six months, ending at $8.627 million.
Material Changes Versus the Prior Comparable Period
- Quarterly operating expenses decreased 35.7% from $4.381 million to $2.818 million; six-month operating expenses decreased 15.1% from $6.194 million to $5.261 million.
- The reductions were primarily attributed to lower stock-based compensation, lower laboratory and infrastructure spending, and the absence of prior-period severance costs.
- Quarterly net loss improved from $16.107 million to $1.721 million; six-month net loss improved from $16.457 million to $5.804 million.
- The improvement in reported earnings was substantially driven by a favorable change in the fair value of contingent consideration: a $1.082 million gain in the current quarter versus an $11.593 million expense in the prior-year quarter.
- The contingent consideration liability declined from $5.667 million at June 30, 2019 to $4.317 million at December 31, 2019, after contingent shares were issued and a fair-value adjustment was recorded.
- Operating cash use increased 23.2% to $4.376 million for the six months, while financing inflows declined 41.2% because fewer warrants were exercised.
- Common shares outstanding increased to 46,303,924 from 45,273,924 at June 30, 2019. Up to 1,438,122 contingent shares remained issuable under the Enochian Biopharma acquisition agreement.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management states that the company has no sales revenue and expects this to continue until its therapies or products receive marketing approval. Management also states that the company may never become profitable.
- Management believes existing liquidity is sufficient to fund operations for the next twelve months, but additional capital may be required for equipment, research and development, an IND filing for ENOB-HV01, additional HIV programs, and potential acquisitions.
- Future financing could involve equity or debt securities and may not be available on acceptable terms, or at all.
- The company is pursuing preclinical studies and an FDA INTERACT meeting related to ENOB-HV01. Additional studies are planned or underway for ENOB-HV11 and ENOB-HV12 and for cancer immunotherapy programs. No product approvals or commercial revenue are reported.
- The company adopted ASC 842 lease accounting on July 1, 2019, recognizing right-of-use assets of $1.834 million and lease liabilities of $1.931 million at December 31, 2019. Management states the adoption did not materially affect operations or cash flows.
- A prior-period financial statement revision reclassified acquired research-and-development intangible assets from finite-lived to indefinite-lived. The revision reduced prior-period depreciation and amortization and prior-year reported losses.
- The company has related-party exposure through a consulting agreement with G-Tech Bio, LLC. Research and development expense under the agreement was $375,000 for the quarter and $750,000 for the six months. Certain members of the acquisition-related shareholder group control G-Tech.
- On January 31, 2020, the company entered into a license agreement for an HBV treatment under development, requiring a $1.2 million upfront payment, additional milestone-related funding, research support, and a 2% royalty on potential net sales. The upfront payment was made on February 7, 2020.
- Management reported that disclosure controls and procedures were not effective as of December 31, 2019 because of material weaknesses involving limited accounting resources, complex accounting matters, and inadequate segregation of duties. Consultants were engaged, but management expected deficiencies to continue until additional accounting personnel could be hired.
- Management reported no material pending legal proceedings and no material off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Enochian Biosciences, Inc., not Lunai Bioworks Inc.
- Assess cash runway against the company’s stated need for additional funding and its continued absence of revenue.
- Evaluate the concentration and impairment risk associated with the $166.464 million of indefinite-lived intangible assets and goodwill.
- Review the valuation assumptions and potential dilution associated with the $4.317 million contingent consideration liability and 1.438 million potentially issuable contingent shares.
- Assess the probability, timing, cost, and regulatory risks of the planned preclinical, IND, and clinical-development programs.
- Review the material weaknesses in disclosure controls and the effectiveness of remediation efforts.
- Examine the related-party consulting and license arrangements with G-Tech Bio and affiliated parties.